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to the Treatment of Antiretroviral Resistant
HIV Infection
Oliver Bembom, Maya L. Petersen , Soo-Yon Rhee , W. Jeffrey Fessel , Sandra
E. Sinisi, Robert W. Shafer, and Mark J. van der Laan
Abstract
Researchers in clinical science and bioinformatics frequently aim to learn which
of a set of candidate biomarkers is important in determining a given outcome, and
to rank the contributions of the candidates accordingly. This article introduces a
new approach to research questions of this type, based on targeted maximum like-
lihood estimation of variable importance measures.
The methodology is illustrated using an example drawn from the treatment of
HIV infection. Specifically, given a list of candidate mutations in the protease
enzyme of HIV, we aim to discover mutations that reduce clinical virologic re-
sponse to antiretroviral regimens containing the protease inhibitor lopinavir. In
the context of this data example, the article reviews the motivation for covariate
adjustment in the biomarker discovery process. A standard maximum likelihood
approach to this adjustment is compared with the targeted approach introduced
here. Implementation of targeted maximum likelihood estimation in the context
of biomarker discovery is discussed, and the advantages of this approach are high-
lighted. Results of applying targeted maximum likelihood estimation to identify
lopinavir resistance mutations are presented and compared with results based on
unadjusted mutation-outcome associations as well as results of a standard maxi-
mum likelihood approach to adjustment.
The subset of mutations identified by targeted maximum likelihood as significant
contributors to lopinavir resistance is found to be in better agreement with cur-
rent understanding of HIV antiretroviral resistance than the corresponding sub-
sets identified by the other two approaches. This finding suggests that targeted
estimation of variable importance represents a promising approach to biomarker
discovery.
1 Introduction
Researchers in bioinformatics, biostatistics, and related fields are often faced with a large
number of candidate biomarkers and aim to assess their importance in relation to a given
outcome. Examples include the identification of single nucleotide polymorphisms associ-
ated with the development of cancers, identification of HLA types associated with disease
progression rates, and the identification of viral mutations that contribute to reduced sus-
ceptibility to drug therapy. In some cases, the goal may be to select from a list of candidates
those biomarkers with underlying causal relationships to the outcome. In others, the re-
searcher may wish to rank the importance of a set of candidate biomarkers in terms of their
contributions to determining the outcome.
In this article we introduce a novel method for biomarker discovery based on targeted
maximum likelihood estimation of variable importance measures (VIMs) [1]. As we discuss,
the marginal association of a candidate biomarker with the outcome may not reflect the
biomarker’s mechanistic or prognostic significance. For example, a viral mutation may be
associated with poor response to a given drug without playing any mechanistic role in resis-
tance, as a result of covariates that both predict the presence of the mutation and affect the
outcome via an alternative pathway. VIMs provide a means to rank candidate biomarkers
based on their association with a given outcome, controlling for a large number of additional
covariates [2]. Specifically, given a binary candidate biomarker A, an outcome Y , and a list
of covariates W , the W -adjusted VIM is defined as EW (E(Y |A = 1,W )−E(Y |A = 0,W )).
If one is willing to assume that the measured covariates W are sufficient to control all con-
founding of the effect of A on Y , then the VIM can be interpreted as the average causal effect
of the biomarker on the outcome. In the absence of such an assumption, the VIM remains
an interpretable summary measure of the importance of the biomarker after controlling for
specified covariates.
Several approaches are available to estimate VIMs. Perhaps the most common approach
is based on maximum likelihood estimation of the conditional expectation of the outcome
given the candidate biomarker and covariates. This conditional expectation is then evaluated
at A = 1 and A = 0 for each subject, and the difference is averaged across the population.
Such an approach corresponds to the G-computation formula of Robins [3] applied at a single
time point.
In this article, we show how a recent advance in statistical methodology, targeted max-
imum likelihood estimation, can improve on this standard approach. Targeted maximum
likelihood estimation involves a simple one-step adjustment to an initial estimate of the con-
ditional expectation of the outcome given the biomarker and covariates. This adjustment
reduces bias in the estimate of the VIM and improves robustness to mis-specification of the
likelihood. The theoretical basis for targeted maximum likelihood estimation was recently
published by van der Laan and Rubin [1]. Here, we demonstrate how this work can be
applied in practice to improve standard approaches to biomarker discovery. Throughout the
article, emphasis is placed on practical understanding and implementation of the methods
described.
Targeted maximum likelihood is illustrated using an original data example drawn from
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the treatment of antiretroviral resistant HIV-infection. Using observational clinical data,
we aimed to determine which of a set of candidate viral mutations affect clinical virologic
response to the antiretroviral drug lopinavir, and to rank the importance of these mutations
for drug-specific resistance. The resulting ranking can be used to inform interpretation of
viral genotypes, and to aid clinicians in selecting new antiretroviral treatment regimens with
a greater probability of virologic success.
1.1 Outline.
The article has the following structure. Section 2 introduces the data application and pro-
vides background on the research question and the data structure. In Section 3, we discuss
methods for biomarker discovery, and compare estimation of unadjusted and adjusted as-
sociations between the candidate biomarker and the outcome (E(Y |A = 1) − E(Y |A = 0)
and EW (E(Y |A = 1,W ) − E(Y |A = 0,W )), respectively). Section 4 presents the targeted
maximum likelihood approach to estimation of W -adjusted VIMs, and compares it to a
standard (or G-computation) approach. Implementation and inference using the targeted
approach are discussed both generally and in the context of the data example. Section 5
presents the results of the data analysis, in which the importance of candidate mutations was
assessed using unadjusted, G-computation, and targeted estimates of VIMs. We compare
the results of these methods, and discuss them in the context of current understanding of
HIV antiretroviral resistance. Section 6 concludes with a discussion.
2 Application: Identification of HIV mutations associ-
ated with decreased viral susceptibility to lopinavir.
2.1 Research Question.
Virus resistant to antiretroviral drugs frequently evolves during treatment of HIV infection
and can result in disease progression if new therapies are not initiated. Designing an effective
salvage therapy regimen for an individual infected with resistant virus requires choosing drugs
to which the virus infecting that individual remains sensitive. Tests of viral resistance are
now available to help guide salvage regimen design. However, interpretation of the results of
resistance tests for the purposes of guiding salvage regimen drug choice remains complex.
Assays of viral susceptibility to antiretroviral drugs fall into two general categories:
phenotype-based and genotype-based. Phenotypic resistance tests directly quantify in vitro
drug susceptibility using recombinant virus, while genotypic resistance tests are performed
by sequencing the genes for the viral protease and reverse transcriptase enzymes, the targets
of the major antiretroviral classes. While genotypic tests are less expensive, less complex,
and faster to perform than phenotypic tests, interpretation of the results of genotypic tests
requires linking patterns of viral mutations to in vivo and in vitro resistance.
Data from several sources have been used to inform interpretation of viral genotype. Ob-
served associations between the presence of specific viral mutations and patients’ treatment
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histories suggest that these mutations have been selected for over the course of therapy and
likely contribute resistance to the specific drugs used. In vitro experiments have also provided
insight into the role of individual mutations in determining drug-specific viral susceptibil-
ity. Such experiments include observation of viral evolution in the presence of antiretroviral
drugs, and tests of the ability of mutated viruses to replicate in the presence of drug. The
resulting data on links between viral mutations and susceptibility to antiretroviral drugs
have been combined to create rule-based algorithms for the interpretation of genotype data.
Examples include the French ANRS (National Agency for AIDS Research) algorithm [4],
the Rega algorithm [5], and the Stanford HIVdb program [6]. The Stanford algorithm in
particular provides drug-specific estimates of viral susceptibility using a weighted scoring
system for mutations thought to be associated with resistance. Viral susceptibility to an
entire regimen is calculated by summing susceptibility scores for each drug in the regimen,
yielding a genotypic susceptibility score (GSS). The International AIDS society (IAS) also
publishes an annual drug-specific list of mutations thought to affect viral resistance [7].
Ultimately, the goal of such algorithms is to identify mutations with large impacts on
clinical drug response. We aimed to use data from an observational clinical cohort to rank
a list of candidate resistance mutations based on their importance in conferring resistance
to specific antiretroviral drugs. For the sake of illustration, we focused on resistance to the
commonly used protease inhibitor (PI) drug lopinavir. Rankings like the one presented here
can be used to inform current genotype interpretation algorithms, with the aim of improving
selection of salvage antiretroviral drug regimens for patients infected with resistant HIV
virus.
2.2 Data.
Study sample and inclusion criteria.
Analyses were based on observational clinical data that were primarily drawn from the
Stanford drug resistance database and supplemented with data from an ongoing collaboration
with the Kaiser Permanente Medical Care Program, Northern California. Currently, the
Stanford database contains longitudinal data on over 6,000 patients. Data collected include
use of antiretroviral drugs, results of viral genotype tests, and measurements of plasma HIV
RNA level (viral load) and CD4 T cell count collected during the course of clinical care.
We identified all Treatment Change Episodes (TCEs) in this database that involved
initiation of a salvage regimen containing lopinavir. A TCE was defined using the following
inclusion criteria: 1) change of at least one drug from the patient’s previous antiretroviral
regimen; 2) availability of a baseline viral load and genotype within 24 weeks prior to the
change in regimen; and, 3) availability of an outcome viral load 4-36 weeks after the change
in regimen and prior to any subsequent changes in regimen.
TCEs were excluded if no candidate resistance mutations were present in the baseline
genotype, if the subject had no past experience of PI drugs prior to the current regimen, or if
the newly initiated regimen included hydroxyurea, any experimental antiretroviral drugs, or
any PI drugs other than lopinavir (apart from the low dose of ritonavir that is always given
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with lopinavir). If a single baseline genotype had several subsequent regimen changes that
met inclusion criteria as TCEs, only the first of these regimen changes was included in anal-
yses. Multiple TCEs, each corresponding to a unique baseline genotype, treatment changes,
and outcome, were allowed from a single individual; the resulting dependence between TCEs
was accounted for in the derivation of standard errors and p-values.
Data structure.
Baseline genotype was summarized as a vector A of binary variables Aj that indicate
the presence of a specific mutation in the protease enzyme of HIV (the viral target of
lopinavir). We considered as candidate biomarkers all mutations assessed by the Stan-
ford HIVdb algorithm to be potentially related to resistance to any approved PI drug
(http://hivdb.stanford.edu, accessed 7/18/2006). In total, we considered 30 candidate
PI mutations. In the sections that follow, we describe methods for estimating the importance
of a single candidate biomarker A. In applying these methods to the data example, each of
the candidate mutation Aj, for j = 1, ..., 30, was assessed separately; however, for simplicity
we suppress the subscript j.
Antiretroviral regimens generally combine drugs from more than one class. The following
characteristics of the non-PI component of the salvage regimen were included in the set W
of adjustment variables: indicators of use of each of 13 non-PI drugs; number of drugs
used in each major non-PI class (nucleoside reverse transcriptase inhibitors or NRTI, and
non-nucleoside reverse transcriptase inhibitors or NNRTI); number of drugs and number of
classes used in the salvage regimen for the first time; use of an NNRTI drug in the salvage
regimen for the first time; and number of drugs switched between the previous and salvage
regimen.
W also included the following covariates collected prior to the baseline genotype: indi-
cators of past treatment with each of 30 antiretroviral drugs; number of drugs used in each
of the three major drug classes (PI, NRTI, and NNRTI); history of mono or dual therapy;
number of past drug regimens; date of earliest antiretroviral therapy; highest prior viral load;
lowest prior CD4 T cell count; and most recent (baseline) viral load.
Summaries of non-PI mutations in the baseline genotype (i.e. mutations in the reverse
transcriptase enzyme targeted by the NRTI and NNRTI classes) were also included in the
covariate set W . Known NRTI and NNRTI resistance mutations present at baseline were
summed. In addition, susceptibility scores (standardized to a 0-1 scale) were calculated for
each non-PI antiretroviral drug using the Stanford HIVdb scoring system. These suscepti-
bility scores were included both as individual covariates and as interactions with indicators
of the use of their corresponding drugs in the salvage regimen. Finally, these interaction
terms were summed to yield a non-PI GSS, which summarized the activity of the non-PI
component of the regimen.
The outcome of interest, clinical virologic response, could be conceived as either a binary
indicator of success (defined as achievement of a final viral load below the assay’s lower
limit of detection of 50 copies/mL), or as a continuous measure such as the change in final
log10 viral load over baseline log10 viral load. The analyses reported here used a hybrid
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of these two approaches, aiming to capture the strengths of each. Specifically, given a
baseline measurement Y0 and a follow-up measurement Y1 of log10 viral load, the outcome
of interest Y was defined as follows: If Y1 was above the lower limit of detection (Y1 > 1.7),
then Y = Y1 − Y0; if Y1 was below the detectability limit, however, we imputed Y as the
maximum decrease in viral load detected in the population, which was -4.2 log. Under this
definition, both large drops in viral load from a high baseline and any achievement of an
undetectable viral load (regardless of baseline) were treated as clinical successes. When
several viral loads were measured between 4 and 36 weeks after regimen change, the first
was used; duration from initiation of the salvage regimen until outcome measurement was
included in the adjustment set W .
In summary, each TCE contained a baseline viral genotype, summarized in a vector
A of binary variables defining the presence or absence of each of a list of candidate PI
resistance mutations, a new antiretroviral regimen containing lopinavir initiated following
the genotype, and an outcome Y capturing the change in log10 viral load at 4-36 weeks
(measured before any subsequent changes in regimen) over baseline log10 viral load. In
addition, each TCE contained a setW of adjustment variables, which included summaries of
the non-PI mutations in the viral genotype, as well as covariates collected both prior to and
following the genotype. We aimed to rank the candidate PI-mutations based on their impact
on clinical outcome. In the sections that follow, we discuss several general approaches to
research questions of this type, and discuss their implementation in the context of this data
example.
3 Background: Statistical methods for biomarker dis-
covery
3.1 Marginal vs. adjusted biomarker-outcome associations.
One straightforward approach to biomarker discovery is to assess the unadjusted association
between each candidate biomarker and the outcome, or in other words, to estimate E(Y |A =
1)−E(Y |A = 0) for each candidate A. In some settings the unadjusted association may be
the quantity of interest, particularly when biomarkers can be experimentally manipulated.
For example, if the researcher is able to induce specific mutations in a virus without altering
other key covariates and then to compare viral replication in the presence and absence of
each mutation, then assessment of marginal associations may be an appropriate approach.
In others settings, however, the marginal association between a candidate biomarker and
the outcome can be misleading, or fail to capture the underlying mechanistic relationship of
interest. When dealing with observational or clinical data, covariates are often present that
are both associated with the candidate biomarker and also affect the outcome via a pathway
independent of the biomarker. Such covariates are known in the epidemiologic literature as
confounders.
The HIV data example illustrates how confounding of a biomarker effect can occur.
HIV-infected patients with a given mutation may disproportionately include subjects with an
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extensive treatment history. Because past treatment can strongly affect the presence of other
mutations, past treatment patterns can cause a viral mutation with no effect on resistance to
occur commonly with mutations that do strongly affect resistance. The candidate mutation
may thus appear to confer resistance when in fact it is simply acting as a marker for past
treatment history and the presence of other mutations. The picture is further complicated
by the fact that in HIV infection, past mutations can be “archived” and remain present only
in latent virus. Such archived mutations are not observable, but can still impact clinical
response. We aimed to capture information about these archived mutations via covariates
describing a subject’s treatment history prior to initiation of the salvage regimen. In the
HIV application, then, controlling for the presence of other mutations and for past treatment
history allows us to isolate to what extent any decreased virologic response we observe is
due to the presence of the candidate mutation being considered.
In the absence of residual confounding, the W -adjusted VIM EW (E(Y |A = 1,W ) −
E(Y |A = 0,W )) corresponds to the mean causal effect of the biomarker on the outcome
[2]. In the HIV example, if one is willing to assume that the measured covariates W are
sufficient to control for confounding, adjustment can be used to estimate the causal effect
of each candidate mutation on virologic response, defined as the mean difference in outcome
that would have been observed if the researcher had somehow induced each mutation to
be present versus absent in the entire study population. Depending on one’s philosophy
regarding causal effects, however, one may not be comfortable estimating the effect of a
covariate on which one cannot intervene. Such a non-experimental scenario arises frequently
in the context of biomarker discovery; it is often not possible, even theoretically, to “set”
the level of a candidate biomarker and then to observe the change in outcome.
It also may not be possible to assume that all confounding is controlled for. Additional
confounders may be unknown or simply unmeasured. In addition, even if the measured
covariates W control adequately for confounding, it will not be possible to adjust for all
covariates W if there is insufficient variation, or experimentation, in the occurrence of the
candidate biomarker within strata of W . For example, if a mutation always occurs among
subjects with a specific treatment history, then there is not sufficient information in the
data to estimate the difference in clinical response that would be seen in the presence versus
absence of the mutation in this sub-population. In the data example, the candidate PI
mutations were highly collinear; as a result, for a given candidate mutation, we were unable
to adjust for the presence of the other candidate PI mutations.
When estimation of the causal effect of a candidate biomarker is not feasible, adjustment
of the association between biomarker and outcome for a set of covariates W often remains
desirable. The quantity E(Y |A = 1,W = w) − E(Y |A = 0,W = w) is interpretable as
the difference in mean outcome in the presence versus absence of the candidate biomarker
among subjects or observations with the same values of all covariates (W = w), and the
VIM is simply the mean of these differences with respect to the empirical distribution of W .
Adjustment for covariates W may be desirable as a means to reduce (rather than eliminate)
the dependence of the biomarker-outcome association on the confounding structure of the
data, resulting in a parameter that comes closer to reflecting an underlying mechanistic
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relationship of interest. In addition, unlike unadjusted associations, the W -adjusted VIM
EW (E(Y |A = 1,W )−E(Y |A = 0,W )) does not depend on the joint distribution of A andW ,
and can thus provide more robust findings when applied to populations with similar marginal
distributions of W but distinct confounding structures. For example, populations where
antiretroviral treatment has been used differently in the past may have different relationships
between a candidate protease resistance mutation and the mutations present in other viral
enzymes. Controlling for past treatment and the presence of other mutations aims to improve
the chances that protease mutations identified as important to virologic response in the
current dataset will remain important in future treatment settings.
3.2 Adjustment for post-biomarker covariates.
Selecting which covariates to adjust for when estimating the VIM requires careful thought
and substantial background knowledge about the specific data application to which the
method is being applied. We discussed above the need in the HIV data example to control
for at least two types of baseline covariates, treatment history prior to salvage regimen
initiation and the presence of non-PI mutations. However, in some settings it may also be
desirable to adjust for covariates that occur after, and may be affected by, the candidate
biomarker of interest.
In the HIV data example, the non-PI drugs contained in the salvage regimen, assigned
after assessment of viral genotype, may differ according to the presence of a candidate
mutation. Such a scenario could arise, for example, if the clinician observed a mutation
known to result in high-level resistance, and in response increased the potency of the subject’s
background (non-PI) regimen. To the extent that differences in background regimen impact
clinical response, they have the potential to obscure drug resistance caused by the candidate
mutation. In the causal inference framework, this scenario can be viewed as a (spurious)
indirect effect of the mutation. Our aim is to estimate the direct effect of the mutation on
clinical response, blocking any possible effect the presence of the mutation might have on
the clinician’s choice of background salvage regimen.
One option is to simply include post-biomarker covariates together with baseline co-
variates in the covariate set W . However, interpretation of the resulting W -adjusted VIM
requires careful thought in the context of the specific data example to which it is being
applied. Let Wb denote baseline covariates (occurring prior to the biomarker A), and let Z
denote covariates occurring after, and affected by, A. At an individual level, the quantity
E(Y |A = 1, Z = z,Wb) − E(Y |A = 0, Z = z,Wb) corresponds (under assumptions on con-
founders - see [8]) to the effect of the biomarker on the outcome holding the intermediate
variables Z at a fixed level. The mean of these individual effects provides a population
summary: EW (E(Y |A = 1, Z = z,Wb)−E(Y |A = 0, Z = z,Wb)). In the HIV example, this
quantity would correspond with estimating the mean difference in virologic response if the
researcher induced a candidate mutation to be present versus absent, and assigned a salvage
regimen with fixed characteristics regardless of the presence of the mutation.
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If one is willing to assume the absence of interaction between A and Z, then
EWb(E(Y |A = 1, Z = z,Wb)− E(Y |A = 0, Z = z,Wb))
= EZWb(E(Y |A = 1,Wb, Z)− E(Y |A = 0,Wb, Z)). (1)
In other words, averaging over the empirical distribution of the post-biomarker covariates,
Z, will not alter the estimated VIM, and thus the direct effect of interest can be estimated by
simply including post-biomarker covariates together with baseline covariates in the adjust-
ment set W . In the HIV example, the no-interaction assumption corresponds with assuming
that the effect (or adjusted VIM) for each candidate PI mutation does not differ depending
on the characteristics of the background regimen, a reasonable assumption given that PI
mutations are not expected to affect response to non-PI drugs. In the analyses reported,
characteristics of the (non-PI) background regimen were therefore included in the adjustment
set W .
An additional common post-biomarker covariate is the duration between assessment of
the biomarker and measurement of the outcome. To the extent that this duration is variable,
differs depending on the presence of the biomarker, and affects the outcome, it has the
potential to obscure the VIM of interest. In the HIV example, the outcome viral load
was assessed between 4 and 36 weeks following salvage regimen initiation, and viral loads
observed sooner following salvage initiation were likely to be higher. If the presence of a
candidate mutation affected the time at which viral load was monitored, duration until the
outcome was monitored could thus serve as an additional source of a spurious indirect effect.
In the analyses reported in this article, time until viral load assessment was included as a
covariate in W , according to the following rationale: 1) If the presence of the candidate
mutation did not affect duration until outcome assessment, this duration could not serve as
a source of an indirect effect, and inclusion of duration as a covariate did not require any
additional assumptions; however, given the association between duration and the outcome,
the inclusion of this covariate would be expected to improve efficiency. 2) If the presence of
the candidate mutation did affect duration until outcome assessment, we wished to control
for this indirect effect; inclusion of duration as a covariate allowed us to do this, again under
the no interaction assumption (interpretable in this case as assuming that the effect of the
mutation on virologic response did not vary over time). We note that inclusion of duration
until outcome assessment is one possible way to address a potentially informative censoring
mechanism; alternatives, such as the use of inverse probability weights [9], are beyond the
scope of this article.
In summary, depending on the data application, inclusion of post-biomarker covariates
in the adjustment set W may be warranted. However, such a decision requires careful
consideration of the interpretation of the resultingW -adjusted VIM. In the following section,
we return to the estimation of this parameter.
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3.3 A traditional approach to the estimation of variable impor-
tance measures.
A common approach to the estimation of W -adjusted VIMs focuses on estimation of the
conditional expectation E(Y |A,W ) of the outcome given the biomarker and covariates, using
standard maximum likelihood estimation. Given an estimate of E(Y |A,W ), the VIM can
be estimated by simply evaluating this object at the values A = 0 and A = 1, and averaging
the resulting differences across the population. Such an approach of intervening on the
likelihood corresponds to the G-computation formula of Robins [3], applied in the setting
of a single time-point. Frequently, the number of covariates W is large and the functional
form of E(Y |A,W ) is unknown. Multiple algorithms are available to learn this form data-
adaptively; examples include classification and regression trees [10], random forests [11],
least angle regression [12], and the Deletion/Substitution/Addition (D/S/A) algorithm [13].
Either cross-validation or some form of penalization of the likelihood are generally used to
select the level of model complexity providing the optimal bias-variance trade-off for the
purposes of prediction; in the case that Y is continuous, this corresponds to selecting the
level of complexity which minimizes the mean squared error.
Such an approach is appropriate if the goal of the analysis is to find the optimal predictor
of the outcome Y given A and W . However, biomarker discovery often aims instead to
evaluate a list of candidate biomarkers, rank them in terms of importance, and identify
those significantly associated with the outcome. When the goal of analysis is to estimate the
W -adjusted VIM for each of the candidate biomarkers, a different estimation approach may
be warranted. To understand why, consider the HIV data example.
The number of covariates in this application, as in many biomarker applications, is very
large, consisting of multiple mutations, salvage regimen characteristics, baseline character-
istics of the subject such as viral load and CD4 count, and the subject’s past antiretroviral
treatment experience. A conventional approach would attempt to choose the model that
best predicts virologic response as a function of the candidate mutation and these covari-
ates. Given the large number of covariates, a reasonable approach would be to apply some
data-adaptive regression algorithm to select this model. However, standard data-adaptive
approaches aim to achieve the optimal bias-variance tradeoff for the entire conditional ex-
pectation of Y given A and W . Because the VIM is a much smoother parameter, a model fit
for the purpose of prediction will generally not provide the best bias-variance trade-off for
the purpose of estimating the VIM. Furthermore, a predictor constructed using conventional
methods is likely to involve multiple terms that do not contain the candidate mutation; for
example, baseline viral load and CD4 T cell count are likely to make important contribu-
tions to virologic response regardless of mutation profile. Mis-specification of such terms in,
for example, a traditional multivariable regression model can result in bias in the estimated
effect of the mutation, even under the null hypothesis of no mutation effect.
In summary, in the context of biomarker discovery, prediction is often not the under-
lying goal of analysis. Traditional approaches invest in achieving a good fit for the entire
conditional expectation of Y given A and W ; however such a fit is not targeted at the
biomarker-specific VIM of interest. In contrast, targeted maximum likelihood estimation of
9
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the VIM, introduced in the following section, allows the researcher to focus on the impor-
tance of each mutation in turn, reducing bias in the adjusted VIM estimate and improving
robustness to mis-specification of the model for E(Y |A,W ).
4 Targeted maximum likelihood estimation.
In this section, we provide a practical overview of targeted maximum likelihood estimation
of variable importance measures. The formal statistical theory behind targeted maximum
likelihood has been published elsewhere [1]. Here, our aim is to make this material practically
accessible to the practitioner who wishes to apply targeted maximum likelihood estimation
to improve biomarker discovery.
The density of the observed data O = (W,A, Y ) is defined by the marginal distribution
of covariates W , the conditional distribution P (A|W ) of the biomarker given covariates,
and the conditional distribution P (Y |A,W ) of the outcome Y given A and W . Unlike
standard approaches to VIM estimation (which rely entirely on estimating E(Y |A,W )),
targeted maximum likelihood estimation also involves estimation of P (A|W ). This estimate
of the conditional distribution of the biomarker given covariates is used to update an initial
estimate of E(Y |A,W ) in such a way that evaluating the updated estimate at A = 1 and
A = 0 and taking the empirical mean results in an estimator of the W -adjusted VIM with
reduced bias and improved robustness to model mis-specification.
Denote our parameter of interest, the W -adjusted VIM, by
θ ≡ EW
[
E(Y |A = 1,W )− E(Y |A = 0,W )
]
. (2)
To ensure that this parameter is well-defined, we will assume that
0 < P (A = 1|W ) < 1 (3)
with probability one, or in other words, that some variation in the biomarker exists within
each stratum of W .
We first summarize the basic steps involved in targeted maximum likelihood estimation
of θ before going on to discuss each in detail, illustrated in the context of the data example.
Implementation of the targeted maximum likelihood involves the following steps:
1. Estimating the conditional expectation of Y given A and W . We denote this initial
estimate Q0n(A,W ).
2. Estimating the conditional distribution of the biomarker given covariates. We denote
this estimate g0n(A,W ).
3. For each subject, calculating a specific covariate, based on the subject’s observed values
for A and W and using the estimate g0n(A,W ). We denote this covariate h(A,W ).
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4. Updating the initial regression Q0n(A,W ) by adding the covariate h(A,W ) and esti-
mating the corresponding coefficient by maximum likelihood, holding the remaining
coefficient estimates fixed at their initial values. We denote this updated regression
Q1n(A,W ).
5. Evaluating the updated regression at A = 1 and A = 0 to get two predicted outcomes
for each subject and taking the empirical mean of the difference across the population
to obtain a targeted estimate of the VIM.
4.1 An initial estimate of E(Y |A,W ).
The first step in targeted maximum likelihood estimation consists of obtaining an initial
estimate of the conditional expectation E(Y |A,W ) of Y given A and W , as one would do
in a standard G-computation approach to variable importance estimation. The number
of covariates W will often be large, and the functional form for E(Y |A,W ) will often be
unknown. In this case, as discussed in Section (3.3), a range of data-adaptive approaches
are available to obtain an estimate Q0n(A,W ).
In the HIV data example, we were faced with a large number of candidate covariates,
detailed in Section 2.2. These included mutations other than the candidate mutation of
interest (incorporated both as individual covariates and summarized using measures such
as drug-specific susceptibility scores), various summaries of past treatment history, baseline
laboratory data on CD4 T cell count and viral load, time until outcome assessment, and
summary measures of the background regimen and its estimated activity given baseline
genotype. To reduce the size of the adjustment set W , we first performed a dimension
reduction based on the unadjusted association of each candidate covariate with the outcome
Y ; the covariates with the 50 smallest p-values were retained.
Following this dimension reduction, we applied the D/S/A algorithm [13] to obtain an
initial estimate Q0n(A,W ) based on the remaining 50 covariates. The D/S/A algorithm is
a data-adaptive algorithm for polynomial regression that generates candidate predictors as
linear combinations of polynomial tensor products in continuous and/or binary covariates.
These candidate estimators are indexed by the number and complexity of the terms, and the
optimal candidate is selected using cross-validation. In estimating E(Y |A,W ), the D/S/A
algorithm considered candidate estimators with up to two-way interaction terms and a max-
imum quadratic order for each term. Specifically, E(Y |A,W ) was modelled by first selecting
a model for E(Y |W ) with a maximum of 10 terms, then adding the term A to the selected
model, and finally re-running the algorithm to select a model for E(Y |A,W ), forcing previous
terms to be in the model and allowing the D/S/A algorithm to add up to 5 new terms.
This initial estimate of E(Y |A,W ) was evaluated at A = 1 and A = 0, and the empirical
mean of the difference was used to estimate VIMs according to the G-computation approach.
In other words, the G-computation estimate of the VIM was given by
θG−compn =
1
n
n∑
i=1
Q0n(1,Wi)−Q0n(0,Wi). (4)
11
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The targeted maximum likelihood estimate of the VIM also made use of this initial
estimate Q0n, updated according to the following steps.
4.2 Estimation of P (A|W ).
The next step in the targeted estimation of VIMs consists of estimating the conditional
distribution of A givenW . In the current application, A is binary so that a logistic regression
model can be used for this purpose. In fitting such a model, we first employed the same
dimension reduction onW as used in fitting E(Y |A,W ). We then used the D/S/A algorithm
to data-adaptively select an appropriate logistic regression model for the probability of having
the candidate mutation given W . The D/S/A algorithm was run with a maximum of two-
way interactions, a maximum quadratic order for each term, and a maximum of ten terms.
The practical performance of the targeted maximum likelihood estimator can be improved
somewhat by ensuring that no estimated treatment probabilities g0n(A,W ) are very close to
zero; here, we do so by setting estimated treatment probabilities smaller than 0.01 to 0.01.
4.3 Calculation of h(A,W ) and update of Q0n(A,W ).
Using the resulting estimate g0n(A,W ), the next step is to calculate the following covariate,
denoted h(A,W ), for each subject:
h(A,W ) ≡
(
I(A = 1)
g0n(1,W )
− I(A = 0)
g0n(0,W )
)
. (5)
A one-step adjustment to the initial regression estimate Q0n(A,W ) is performed by adding
the covariate h(A,W ) to this regression and obtaining a maximum likelihood estimate n of
the corresponding coefficient , holding all other coefficient estimates fixed at their initial
values. The estimate n can thus be obtained by regressing Y on h(A,W ) using Q
0
n(A,W )
as an offset. The updated estimate Q1n(A,W ) is then given by
Q1n(A,W ) = Q
0
n(A,W ) + nh(A,W ). (6)
The corresponding targeted estimate of the marginal VIM is given by
θT−MLEn =
1
n
n∑
i=1
Q1n(1,Wi)−Q1n(0,Wi). (7)
The targeted maximum likelihood estimator is thus identical to the G-computation estimator
described above except that it is based on the updated regression fit Q1n(A,W ) rather than
the initial fit Q0n(A,W ).
4.4 Advantages of targeted maximum likelihood estimation.
Standard approaches to the estimation of variable importance rely entirely on the estimation
of the conditional expectation of the outcome given the biomarker and covariates. The
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approach presented here provides a means to target this regression estimate specifically at the
parameter of interest (in this case the W -adjusted VIM). In the context of the HIV data, for
example, targeted maximum likelihood estimation ofW -adjusted variable importance allows
us to obtain a targeted estimate of the significance of each candidate resistance mutation in
turn.
If the initial estimate of E(Y |A,W ) is based on standard multivariable or logistic regres-
sion, implementing the targeted maximum likelihood estimator is simply a matter of adding
a covariate to the initial regression and estimating the corresponding coefficient by maximum
likelihood. The result of this single-step adjustment is a reduction in bias for the parameter
of interest [1]. In addition, the targeted VIM estimate has improved robustness to model
mis-specification in comparison to a G-computation estimate based on the initial regression
fit. Specifically, the G-computation estimator is consistent only if the model for E(Y |A,W )
is correctly specified. In contrast, the targeted maximum likelihood estimator is consistent
if the model for either E(Y |A,W ) or P (A|W ) is correctly specified. This added robustness
is particularly valuable in contexts where the dependence of the biomarker on covariates is
easier to model than the dependence of the outcome on biomarker and covariates.
Standard errors estimates and p-values for the targeted maximum likelihood VIM es-
timator can be obtained using the non-parametric bootstrap. This approach provides a
straightforward means to address dependence between observations, as occurred in the data
example because a single subject could contribute more than one TCE to the analyses.
The non-parametric bootstrap also offers an opportunity to perform re-sampling-based ap-
proaches to multiple testing without substantial additional computer time.
5 Results: Identification of HIV mutations associated
with decreased viral susceptibility to lopinavir.
In this section, we present the results of applying three different approaches to assess the im-
portance of each of a set of candidate PI mutations in determining clinical virologic response
to lopinavir:
1. Estimation of the unadjusted association E(Y |A = 1) − E(Y |A = 0), based on uni-
variate regression of Y on A.
2. Estimation of the W -adjusted VIM EW (E(Y |A = 1,W )− E(Y |A = 0,W )), based on
the G-computation estimator (4).
3. Estimation of the W -adjusted VIM EW (E(Y |A = 1,W )− E(Y |A = 0,W )), based on
the targeted maximum likelihood estimator (7).
Four hundred and one TCEs among 372 subjects involved initiation of a salvage regimen
containing lopinavir and met all of our inclusion criteria. The frequency of the various
candidate PI mutations among these TCEs is summarized in Table 1. Here and subsequently,
mutations are denoted by the position of the change in the HIV protease enzyme, followed by
13
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Table 1: Frequency of candidate protease inhibitor mutations among the 401 TCEs included
in the analysis. VIMs were estimated only for those mutations which occurred in at least 20
TCEs. For those mutations present in at least 20 TCEs, % Violations gives the percentage of
TCEs with fitted mutation probabilities < 0.05 or > 0.95; a high percentage may reflect a lack
of variation in the distribution of the mutation that can lead to unreliable VIM estimates.
Mutation Frequency % Violations
10FIRVY 217 3%
16E 9 –
20IMRTVL 115 0%
23I 4 –
24IF 16 –
30N 45 64%
32A 0 –
32I 21 58%
33F 44 51%
36ILVTA 141 0%
46ILV 143 0%
47V 17 –
48VM 16 –
48AST 1 –
50V 5 –
50L 0 –
53LY 33 0%
54LMST 36 84%
54VA 84 0%
63P 311 5%
71TVI 181 0%
73CSTA 66 35%
82AFST 100 6%
82MLC 4 –
84AV 73 28%
84C 2 –
88DTG 44 36%
88S 9 –
90M 171 0%
14
http://biostats.bepress.com/ucbbiostat/paper221
a letter indicating the amino acid that has been substituted (e.g. 53LY refers to a substitution
of leucine or tyrosine at protease position 53). As discussed in Section 3 and stated formally
in equation (3) in Section 4, adjustment for covariates W requires that there be variation
in the presence of the biomarker within strata of W . In order to help ensure sufficient
variation and the ability to control adequately for confounding, we estimated VIMs only for
those mutations which occurred in at least 20 TCEs; among the mutations that had to be
excluded based on this criterion are the important lopinavir resistance mutations 50V, 84C,
and 88S. In addition, we assessed the extent of variation among the remaining mutations
by examining the fitted probabilities g0n(A,W ). For a few of these mutations, most notably
54LMST and 30N, a high proportion of the fitted probabilities were less than 0.05 or greater
than 0.95, suggesting that they may not exhibit enough variation within strata of W to
allow for reliable VIM estimation. The results presented for these mutations should thus be
interpreted with care.
It was not clear based on background knowledge whether the presence of mutations
affected the duration until the outcome viral load was measured. We investigated this
potential dependence by using box plots to compare the distribution of outcome monitoring
times in the presence versus absence of each mutation. These plots did not suggest any major
differences in the distribution of monitoring times according to the presence or absence of
any mutation. In addition, we fit a data-adaptive model of the conditional hazard of viral
load monitoring over time in order to examine the potential dependence of monitoring on the
presence of candidate mutations and baseline covariates. The data-adaptively selected model
included as single covariate the time that had elapsed since initiation of the new treatment
regimen. Together, these findings suggest that the presence of particular mutations did not
strongly affect monitoring time, reducing concern regarding the assumption that mutation
effect was constant over time (discussed in Section 3.2).
Table 2 summarizes the unadjusted associations and estimates of the W -adjusted VIM
based on the G-computation and targeted approaches, along with associated p-value. Table
3 shows three different rankings for the set of candidate mutations, based on the p-values
generated by each of the three approaches. The mutation ranking generated by the current
Stanford scoring system is included for comparison. Inference was based on non-parametric
bootstrap sampling, respecting the subject rather than the TCE as the independent unit
of analysis. The resulting p-values were adjusted for multiple testing using the Benjamini-
Hochberg method [14] to control the false discovery rate (aiming to ensure that the expected
proportion of false positives was 0.05).
Among the 17 candidate PI mutations considered here, the Stanford scoring system iden-
tifies the following seven mutations as major contributors to lopinavir resistance: 82AFST,
54VA, 46ILV, 84AV, 90M, 32I, and 54LMST; the remaining ten mutations are thought to
make minor or no contributions to resistance. The unadjusted association analysis yielded
significant p-values for all but two of the candidate PI resistance mutations (36ILV and 63P).
The significant subset thus included eight mutations thought to have a minor or no effect
on lopinavir resistance. Among these were the mutations 30N and 88DTG, both estimated
to be significantly protective. The protective association of 30N with the outcome was in
15
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Table 2: Estimated VIMs and associated p-values for candidate PI mutations. Score refers to
the resistance score assigned to a mutation by the Stanford HIVdb scoring system (accessed
on 7/18/2006).
Mutation Score Unadjusted G-comp T-MLE
VIM p-value VIM p-value VIM p-value
10FIRVY 2 0.56 < 0.01 0.28 0.12 0.26 0.30
20IMRTVL 2 0.46 0.02 0.39 0.04 0.37 0.04
30N 0 -1.09 < 0.01 -0.60 0.03 -0.20 0.72
32I 10 0.80 0.01 0.63 0.03 0.81 < 0.01
33F 5 0.83 < 0.01 0.49 0.05 1.12 0.02
36ILVTA 1 0.29 0.10 0.39 0.03 0.39 0.04
46ILV 11 0.44 0.01 0.18 0.32 0.13 0.60
53LY 3 0.54 0.04 0.32 0.28 0.32 0.33
54LMST 10 0.67 0.01 0.15 0.55 0.16 0.72
54VA 11 0.86 < 0.01 0.69 < 0.01 0.61 < 0.01
63P 2 0.10 0.57 -0.02 0.90 -0.07 0.72
71TVI 2 0.34 0.03 0.24 0.13 0.24 0.17
73CSTA 2 0.79 < 0.01 0.61 0.02 0.46 0.36
82AFST 20 0.68 < 0.01 0.49 0.02 0.64 < 0.01
84AV 11 0.50 0.02 0.25 0.19 0.49 0.04
88DTG 0 -0.86 < 0.01 -0.50 0.05 -0.37 0.33
90M 10 0.52 < 0.01 0.45 0.02 0.45 0.02
fact ranked the most important of the unadjusted associations. In addition, multiple muta-
tions considered by current knowledge to have only minor effects on resistance (for example,
33F, 10FIRV and 73CST) ranked higher than most of the known major lopinavir resistance
mutations (such as 90M, 32I, and 54LMST).
After adjusting for covariates using G-computation, fewer mutations were identified as
significant, and the resulting ranking agreed to a greater extent with current knowledge.
Specifically, this approach identified eight mutations as having a significant impact on
lopinavir resistance, with an additional two mutations found to be borderline significant
(p-values of 0.051 for 33F and 88DTG). This group of ten mutations includes both four of
the seven major lopinavir resistance mutations and six mutations thought to make minor or
no contributions to resistance. In particular, we note that the mutations 30N and 88DGT
were still identified as having a protective effect.
Targeted maximum likelihood estimation of the adjusted VIM provided the ranking in
best agreement with current knowledge. The significant subset of mutations identified by this
approach included five of the seven major known mutations, and only three minor mutations
(33F, 36ILV, 20IMRTV). The mutation considered most important for lopinavir resistance,
82AFST, was ranked highest, followed by three major known lopinavir resistance mutations
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Table 3: Candidate PI mutations ranked according to the p-values of three distinct VIM
estimates. Score refers to the resistance score assigned to a mutation by the Stanford HIVdb
scoring system (accessed on 7/18/2006). Mutations marked with an asterisk have a negative
VIM estimate, suggesting that they contribute to an improved rather than diminished virologic
response.
Score Unadjusted G-comp T-MLE
Mutation Score Mutation p-value Mutation p-value Mutation p-value
82AFST 20 30N∗ < 0.001 54VA < 0.001 82AFST 0.001
54VA 11 54VA < 0.001 82AFST 0.018 54VA 0.003
46ILV 11 82AFST < 0.001 90M 0.019 32I 0.003
84AV 11 33F < 0.001 73CSTA 0.019 90M 0.024
90M 10 10FIRVY 0.001 32I 0.033 33F 0.024
32I 10 73CSTA 0.001 30N∗ 0.033 36ILVTA 0.035
54LMST 10 88DTG∗ 0.001 36ILVTA 0.034 84AV 0.037
33F 5 90M 0.003 20IMRTVL 0.043 20IMRTVL 0.039
53LY 3 32I 0.014 33F 0.051 71TVI 0.174
10FIRVY 2 46ILV 0.015 88DTG∗ 0.051 10FIRVY 0.301
73CSTA 2 54LMST 0.015 10FIRVY 0.123 53LY 0.330
20IMRTVL 2 84AV 0.016 71TVI 0.130 88DTG∗ 0.330
71TVI 2 20IMRTVL 0.016 84AV 0.193 73CSTA 0.361
63P 2 71TVI 0.034 53LY 0.277 46ILV 0.600
36ILVTA 1 53LY 0.039 46ILV 0.321 63P∗ 0.719
30N 0 36ILVTA 0.097 54LMST 0.551 30N∗ 0.719
88DTG 0 63P 0.574 63P∗ 0.898 54LMST 0.719
(32I, 54AV and 90M). Unlike G-computation, targeted maximum likelihood also identifies
the major lopinavir resistance mutation 84AV as a significant contributor to resistance.
In addition, unlike the other two approaches, it did not rank either 88DGT or 30N as
significantly protective. Two mutations thought to be important for lopinavir resistance,
46ILV and 54LMST, were not identified by targeted VIM estimation. However, Table 1
shows that for the mutation 54LMST, 84% of observations had fitted mutation probabilities
< 0.05 or > 0.95, suggesting a lack of variation in 54LMST within strata ofW that may lead
to unreliable VIM estimates. In addition, in vitro experiments examining the effect of 46ILV
on viral phenotype suggest that this mutation may in fact be less important for lopinavir
resistance than previously thought [15].
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6 Discussion.
6.1 HIV resistance mutations.
The current article discussed how targeted maximum likelihood estimation of variable im-
portance measures can be used in biomarker discovery. Motivation for the method, details
of its implementation, and interpretation of results were illustrated using an example from
the treatment of HIV infection. We estimated the importance of each of a set of candi-
date PI mutations for clinical virologic response to treatment with the commonly used PI
drug lopinavir, adjusted for covariates including treatment history, the presence of non-PI
mutations, and characteristics of the background regimen.
Our analysis suggests that targeted maximum likelihood estimation of VIM represents
a promising new approach for studying the effects of HIV mutations on clinical virologic
response to antiretroviral therapy. The subset of mutations identified by this approach as
significant contributors to lopinavir resistance was in better agreement with current knowl-
edge than the subsets identified by an unadjusted analyses or the G-computation approach.
Specifically, the unadjusted analysis identified as significant all but two of the candidate
mutations, including eight mutations thought to have a minor or no effect on lopinavir
resistance. G-computation reduced the significant subset to four of the seven mutations
thought to make major contributions to lopinavir resistance, while still including six mu-
tations thought to make only a minor or no contribution to resistance. In contrast, the
significant subset of mutations identified by targeted maximum likelihood included five of
the seven major known mutations and only three minor mutations. In addition, the specific
ranking provided by targeted VIM estimation also agreed better with current understanding
than did the rankings generated with alternative methods.
While targeted VIM estimates were able to replicate most known findings, they also sug-
gested that the mutation 46ILV may be less important in determining resistance to lopinavir
than previously thought. As mentioned in Section 5, this finding has some support from
in vitro studies [15], suggesting that a more detailed investigation of the role of this muta-
tion may be warranted. Taken as a whole, the promising results reported here suggest that
further application of the targeted VIM approach may result in improvements to existing
genotypic interpretation algorithms.
6.2 Targeted maximum likelihood.
As illustrated in this article, targeted maximum likelihood estimation offers an improvement
in robustness over conventional likelihood-based approaches that is straightforward to imple-
ment using standard statistical software. Specifically, the approach remains consistent if we
mis-specify how virologic response depends on the mutation and all covariates, but correctly
model how the presence of the mutation depends on covariates. The resulting targeted VIM
estimates provide a means to both rank candidate biomarkers and to identify a subset of
biomarkers as relevant for a given outcome. The current article focused primarily on VIM
for a continuous outcome. Generalization to a binary outcome modelled using logistic re-
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gression is straightforward, as was mentioned briefly. The method can further be generalized
to alternative approaches for obtaining an initial estimate of E(Y | A,W ).
The double robust variable importance estimator introduced by van der Laan [2] provides
similar advantages to the targeted VIM estimate in terms of improved robustness to model
mis-specification. However, the targeted approach has several practical advantages. Many
practitioners are more familiar with regression-based approaches, as used by the targeted
estimator, than with the estimating function methodology employed by the double robust
estimator. In addition, the targeted maximum likelihood VIM estimator can in many cases
be implemented using standard software, in a natural extension of common regression ap-
proaches. These practical advantages, together with the improvement in robustness, make
targeted maximum likelihood estimation of variable importance a promising new approach
to biomarker discovery.
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